NMDE Flashcards
Epidemiology UC
2-10 per 100,000 Increased in females Increased in Caucasians Bimodal peaks 15-25 and 55-65 FHx component
Decreased in smokers
Symptoms & signs of UC
relapsing and remitting in nature Diarrhoea PR bleeding Frequency of stools, associated with urgency Fatigue and malaise Fever Mucus discharge
Tachycardia
Fever
Abdominal tenderness
Disease features of UC
Only affects the colon, always affects the rectum Inflammation limited to the mucosa Mucosal atrophy, walls appear thin Ulcers are superficial with a broad base No skin lesions No mural thickening, no strictures, no fistulas No malabsorption Malignant potential No recurrence post-op
Pathophysiology of UC
Defects in host interaction with intestinal bacteria
Intestinal epithelial dysfunction
Inappropriate mucosal immune responses
TH17 and TH2 are increasingly active
Defects in epithelial tight junctions increased passage of bacteria to cause a reaction
Increased cytokine activity
No specific gene.
Investigations for UC
FBC - anaemia or thrombocytosis
LFTs - raised ALP, hypoalbuminaemia, hypokalaemia, hypomagnesaemia
Raised ESR and CRP
Test iron, B12, folate
Foetal calprotectin, usually used for monitoring.
Stool samples for infection,
ANCA positive
Colonoscopy/sigmoidoscopy + biopsy - abnormal erythematous mucosa with ulceration - biopsy for confirmation
Abdominal X-ray to check for perforation.
Double contrast barium enema - lead piping
Foetal calprotectin, usually used for monitoring
Can use CT enterography
Measuring severity of UC
Using Truelove & Witt’s severity index
MILD - diarrhoea <4 times /day, no anaemia, no fever, no tachycardia, no weight loss
MODERATE - diarrhoea 4/5 times per day, Small amount of blood in stool, no fever, no tachycardia, raised CRP (mild)
SEVERE - diarrhoea 6+ times a day, blood in stool, fever, tachycardia, anaemia, raised CRP
Extracolonic manifestations of UC
Uveitis Pleuritis Erythema nodosum Ankylosing spondylitis Pyoderma gangrenosum
Primary sclerosing cholangitis
MS
Management of UC - inducing remission
- Amniosalicylates - mesalazine
- Corticosteroids - oral prednisolone
- Immunomodulators - azathioprine, methotrexate, ciclosporin
- Mabs - Infliximab in severe cases
- Surgery
Complications of UC
Bleeding
Toxic megacolon
Increased risk of colon cancer
Perforation
Epidemiology of Crohn’s
1-6 per 100,000 Increased in females Increased in Caucasians Bimodal age peak 15-25 and 55-65 Genetic link - NOD2
Smoking is a big risk factor
Most common in ileocaecal
Symptoms of Crohn’s
Diarrhoea PR bleeding Abdominal pain Weight loss Fatigue Mouth ulcers
Features of Crohn’s
Any part of GI tract Transmural, can form strictures Skip lesions Oedema and loss of mucosal texture Triggered by emotional stresses or smoking Cobblestone appearance Ulcers deep and knife like Fistulas common Fat/vitamin malabsorption Malignant potential if in colon Recurrence post-op is common
40% ileocecal, 30% small intestine, 25% colon
Pathophysiology of Crohn’
Defects in host interaction with intestinal bacteria
Intestinal epithelial dysfunction
Inappropriate mucosal immune responses
TH17 and TH2 are increasingly active
Defects in epithelial tight junctions increased passage of bacteria to cause a reaction
Increased cytokine activity
NOD 2 gene
Investigations in Crohn’s
FBC - anaemia
Raised CRP
Nutrient deficiency, B12, folate
LFTs hypoalbuminaemia
Stool culture for C.diff
ASCA (not ANCA as in UC)
Endoscopy - ileocolonoscopy + biopsies, occasionally OGD
Abdominal X-ray for perforation
Small bowel follow through - cobblestone appearance
Can have CT enterography
Management of Crohn’s - inducing remission
- Steroid - prednisolone
- Aminosallicylate - mesalazine
- Azathioprine / mercaptopurine
- Methotrexate
- Infiximab or adalimumab
Surgery is last line
Management of Crohn’s - maintenance
Azathioprine or mercaptopurine
Extraintestinal features of Crohn’s
Uveitis Migrating polyarthritis Ankylosing spondylitis Clubbing Pyoderma gangrenosum (greater incidence than in UC) Erythema nodosum Aphthous ulcers
Classification of Crohn’s disease
Crohn’s disease activity index
<150 remission, 150-300 active, 300+ severe
Depends on number of stools, pain, well being, extra intestinal manifestations, pyrexia, etc.
Harvey Bradshaw Index
<4 = remission, 5-8 moderate, 8+ severe
Complications of Crohn’s
Small bowel obstruction Perianatal fistula/fissure bowel fistula Bowel perforation GI blood loss Cancer
Causes of upper GI bleeding
Gastritis - dyspepsia
Oesophagitis - dyspepsia , worse on lying
Gastric/duodenal ulcer - nausea, vomiting, weight loss, dyspepsia
Oesophageal/gastric varices - Hx of liver disease, alcohol excess
Cancer - malaise, weight loss, vomiting, early satiety
Mallory-Weiss tear = young, history of vomiting, small amounts
Gastric/duodenal erosions = NSAID or alcohol history, epigastric pain
Drugs = aspirin, NSAIDs, steroidsm thrombolytics, anticoagulants
Rare = bleeding disorders, aorto-enteric fistula, Meckel’s diverticulum
Symptoms and Signs of upper GI bleeding
Fresh haematemesis or coffee grounds
Melaena
Medication and alcohol history
Tachycardic and hypotensive
Cap refill may be reduced
Postural BP drop
Anaemia - pallor
Stigmata of liver disease - hepatic flap, caput medusa, ascites, hepatomegaly, spider naevi
Investigations for GI bleeding
FBC - haemoglobin and MCV (if low MCV, may be chronic)
U&E - raised urea to creatinine ratio
LFTs - clotting and signs of chronic liver disease
Upper GI endoscopy - NBM for 4 hours.
Classification of GI bleeds
Rockall risk scoring
- relies on BP, HR, endoscopy
Low risk - 0-1, moderate 2-3, severe 4+
Blatchford score
No endoscopy required
Predicts who needs intervention - 6+ needs intervention
Management of upper GI bleed
Non-variceal
- Resuscitate
- Endoscopy within 4/24 hours, urgent/non-urgent, no routine PPI pre-endoscopy
Variceal
- Resuscitate
- Terlipressin
- Variceal band, ligation/adrenaline injections/ TIPS/ glue
- Balloon tamponade - Sengstaken-Blakemore tube
- antibiotics